Biopharma | May 05, 2026
Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025
The private funding rose 38% amid growing international collaborations and CDMO demand
The private funding rose 38% amid growing international collaborations and CDMO demand
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
The biggest highlight was Project Vimana, a drone-deployed battlefield trauma surgery system engineered to bring life-saving surgical intervention
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
Subscribe To Our Newsletter & Stay Updated
